The transplantation of human embryonic stem cell (hESC)-derived insulin-producing b cells for the treatment of diabetes is finally approaching the clinical stage. However, even with state-of-the-art differentiation protocols, a significant percentage of undefined nonendocrine cell types are still generated. Most importantly, there is the potential for carry-over of non-differentiated cell types that may produce teratomas. We sought to modify hESCs so that their differentiated progeny could be selectively devoid of tumorigenic cells and enriched for cells of the desired phenotype (in this case, b cells). Here we report the generation of a modified hESC line harboring two suicide gene cassettes, whose expression results in cell death in the presence of specific pro-drugs. We show the efficacy of this system at enriching for b cells and eliminating tumorigenic ones both in vitro and in vivo. Our approach is innovative inasmuch as it allows for the preservation of the desired cells while eliminating those with the potential to develop teratomas.
INTRODUCTION
Clinical trials have already been initiated for the treatment of type 1 diabetes with hESC-derived b cell progenitors (Schulz et al., 2012) , and newer approaches with functional b-like cells are lining up (Pagliuca et al., 2014; Rezania et al., 2014) . However, for all their promise, hESCs are not without limitations. While the proportion of b-like cells obtained is relatively high (30%-40%) (Pagliuca et al., 2014; Rezania et al., 2014) , a significant percentage of undefined cell types are also generated (Dominguez-Bendala et al., 2016; Pagliuca et al., 2014) . Most importantly, non-differentiated escapees may produce teratomas upon transplantation (Kroon et al., 2008) . Although recent protocol refinements have reduced this risk, the foreseeable implementation of hESC-based therapies in thousands of patients calls for caution. One single case of hESC-derived tumors may set the field back for years.
To address these concerns, we set out to engineer hESC lines with control mechanisms allowing for the selective ablation of both tumorigenic cells and cells differentiated along undesirable fates. We hypothesized that constructs of our invention would impart such selectivity when stably integrated within the host genome. Given its clinical immediacy, we decided to focus on an insulin-producing cell differentiation model, even though our system could be customized for any cell type. In such a model, cells are engineered with two suicide gene cassettes. One of them (herpes simplex virus thymidine kinase, or HSV-TK) is activated only in cells that resume/continue tumorigenic proliferation. The second (nitroreductase [NTR] ) is active in all cells unless they express insulin, in which case it is permanently excised out of the genome. HSV-TK and NTR impart sensitivity to ganciclovir (GCV) (Fareed and Moolten, 2002) and CB1954 (Grove et al., 1999) , respectively, which have been tested clinically (Searle et al., 2004; Williams et al., 2015) . In our design, the NTR cassette, flanked by loxP sites, is eliminated upon expression of Cre by the human insulin promoter (Kuhn and Torres, 2002) . Therefore, insulin-expressing cells are rendered insensitive to CB1954. HSV-TK is driven by the telomerase promoter, which is active only in undifferentiated cell types (Albanell et al., 1999) . This makes proliferating cells sensitive to GCV. Thus, our method provides a double fail-safe control such that (1) only insulin + , non-proliferating cells survive selection; (2) cells that may de-differentiate after transplantation (Fujikawa et al., 2005) (and in which NTR was lost with the onset of insulin expression) may still be selectively killed in vivo by GCV, leaving the rest of the graft intact; and (3) undifferentiated cells are sensitive to two pro-drugs, Figure 1 . Genetically Modified lH1 Cells Are Sensitive to the Pro-drugs Ganciclovir (GCV) and CB1954 (A) The structure of construct A comprises: (1) a constitutive cytomegalovirus promoter-enhancer hybrid (CMV)-driven codon optimized (co) nitroreductase gene (NTR); (2) a neomycin resistance gene (NeoR); and (3) LoxP sites flanking the above two cassettes in their entirety. Construct B consists of: (1) a human telomerase reverse transcriptase promoter (hTERT)-driven codon optimized (co) herpes simplex virus thymidine kinase S39 mutant gene (HSV-TK/s39); (2) a human insulin promoter (hIP)-driven codon optimized Crerecombinase gene (Cre); and (3) a puromycin resistance cassette. When the insulin promoter is active, Cre recombinase is produced, and (legend continued on next page) making it less likely for tumorigenic cells to survive in case one single drug was insufficient to destroy 100% of them, or if they became resistant to one pro-drug due to spontaneous mutations of the relevant suicide gene (Kotini et al., 2016) . No other method reported thus far offers the same degree of safety and specificity, as conventional suicide gene-based strategies bring about the destruction of the entire graft or do not enrich for the cells of therapeutic interest. Our results offer proof-of-principle of this approach and open the door to the subsequent targeting of these constructs to specific ''safe harbor'' locations within the genome of clinical-grade hESCs.
RESULTS
Suicide Cassette Construction DNA was synthesized by GenScript (Piscataway, NJ). Owing to the size of both suicide cassettes, we generated two constructs that could be independently transfected. Figure 1A shows the composition of constructs A (loxP-CMV-NTRloxP) and B (hTERTP-HSV-TK-hiP-Cre), as well as their predicted function. The main elements of construct A are: (1) loxP sites flanking a region that is excised by Cre (Nagy, 2000) . (2) Nitroreductase (NTR, T41L/N71S mutant). NTR is a flavoenzyme homodimer with flavin mononucleotide (FMN) cofactors, encoded by the E. coli nsfB/nfnB gene (Searle et al., 2004) . CB1954 [5-(aziridin-1-yl)-2,4-dinitrobenzamide] is reduced by the FMN to a 4-hydroxylamino derivative, which becomes a cytotoxic DNA crosslinking agent (Grove et al., 1999) . Since virus-mediated expression of NTR in tumor cells sensitizes them to CB1954, this strategy has been tested clinically for several types of cancer (Searle et al., 2004; Williams et al., 2015) . The double mutant T41L/N71S sensitizes cells to CB1954 concentrations up to $15-fold lower than the native enzyme (Jaberipour et al., 2010) . In our construct, the T41L/N71S NTR gene is driven by the CMV promoter. This plasmid is selectable in neomycin/G418. Upon Cre expression, both NTR and neomycin resistance cassettes are eliminated ( Figure 1A ). The main elements of construct B are: (1) HSV thymidine kinase (HSV-TKSR39 mutant). Ganciclovir (GCV) phosphorylation by HSV-TK results in the accumulation of toxic metabolites and cell death (Schipper et al., 2007) . As with NTR, this system has been safely tested for the treatment of cancer (Karjoo et al., 2016; Klatzmann et al., 1998) . Our construct features an enhanced mutant, HSV-TKSR39 (Black et al., 2001) , which also has higher activity at lower doses of the pro-drug (Qasim et al., 2002) . This gene is driven by the human telomerase reverse transcriptase (hTERT) promoter. Somatic cells express hTERT at very low levels or not at all, whereas hESCs and most tumoral cells exhibit high levels of expression. As teratomas have high telomerase activity (Albanell et al., 1999) , the placement of HSV-TK under the control of the telomerase promoter will lead to the selective expression of the suicide gene in undifferentiated hESCs. (2) Cre is a site-specific bacteriophage recombinase (see loxP above) (Nagy, 2000) . In our design, Cre will excise out the sequence comprised between the loxP sites (NTR cassette). Since Cre is driven by the human insulin promoter (Odagiri et al., 1996) , these elements will be eliminated only in cells that express insulin upon differentiation, rendering them insensitive to CB1954 ( Figure 1A ).
Construct B is selectable in puromycin. Backbone sequences for both constructs feature all bacterial replication and expansion elements. We added Kozak sequences (Kozak, 1987 ) wherever needed to ensure maximal expression in human cells. Terminators and enhancers were also placed as required for each expression unit. We applied human codon usage optimization during the synthesis of each construct, as some of the mutant sequences contain codons that are used infrequently in highly expressed human genes. Figure S1 shows nucleotide and amino acid sequences of both constructs. (legend continued on next page)
Modified hESCs Express the Transgenes and Maintain Pluripotency
Clones of the hESC line H1 containing both electroporated constructs were selected using puromycin (for A) and neomycin (for B). Twenty-six double-resistant clones were handpicked, expanded under antibiotic selection and cryopreserved. Genomic PCR to confirm integration of both constructs and qRT-PCR to determine which clones had higher transgene expression was performed ( Figures S2A-S2D ). Based on the results of these assays, clone A (lH1 from now on) was selected for further testing. As shown in Figure 1B , lH1 cells express NTR and HSV-TK transgenes. Expression was stable throughout 23 passages post-transfection ( Figure S2E ). The morphology of lH1 colonies (Figure 1C) and their pattern of expression of pluripotency markers (as determined by flow cytometry [Figures S3A and S3C] , qRT-PCR [ Figure S3B ], and immunofluorescence [ Figure 1D ]) were indistinguishable from those observed in the parental (unmodified) H1 cell line. Karyotype analyses before and after the modification showed no abnormalities induced by transgene insertion (data not shown).
lH1 Cells Are Sensitive to Both GCV and CB1954 In Vitro Kill curves using different dosages for GCV (0.01-1,000 mM) and CB1954 (0.1-300 mM) were performed for lH1 and the parental line. Cell death was quantified by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assays, which helped us determine optimal pro-drug concentration leading to ablation of undifferentiated lH1 cells within 7 days, while preserving the parental line viability. Such concentration was between 10 and 100 mM for both GCV and CB1954 ( Figure S4A ), as reported for other cell types (Felmer and Clark, 2004; Schuldiner et al., 2003) . We used 10 mM for CB1954 and 100 mM of GCV for all subsequent experiments. Figure S4B presents the viability curve of both lH1 and H1 cells when exposed to the above pro-drug dosages for 7 days. Figure 1E presents immunofluorescence (IF) expression of phosphohistone H3 (proliferation)/cleaved caspase-3 (apoptosis) in parental H1 cells (top panel) and lH1 (bottom panel) after treatment with CB1954, GCV, or a combination of both. Controls received just vehicle. As shown there, and in Figure S4D , the parental H1 line is largely insensitive to either pro-drug, while most lH1 cells die after just 2 days of exposure to CB1954 and 6 days of exposure to GCV ( Figure 1F ).
lH1 Cells Differentiate along the b Cell Lineage Next, we proceeded to differentiate both lH1 and its parental cell line into b-like cells (Figures 2A-2C ) (see Experimental Procedures). Gene expression profiles show no statistical differences between lH1 and H1 cells at any stage ( Figure 2C ). The percentage of the pancreatic progenitor markers PDX1 + and NKX6.1 + at the end of stage 4 (PE) (Rezania et al., 2013) was similar for both modified and parental lines (46.4% versus 47.6%, respectively), and aligned with earlier reports (Pagliuca et al., 2014; Rezania et al., 2014; Russ et al., 2015) ( Figure S4C ).
Suicide Constructs Function as Predicted after b Cell Differentiation In Vitro
Once differentiation was completed, we treated both lines with CB1954 and GCV for an additional 7 days and analyzed the resulting populations by flow cytometry (n = 3 independent experiments). Controls were kept in the same conditions, untreated, for the same length of time. As shown in Figure 2D (right panel), the percentage of live lH1 cells that co-express PDX1 + /NKX6.1 + /INS + (a widely accepted b cell signature [Pagliuca et al., 2014; Rezania et al., 2014; Russ et al., 2015] ) differs significantly between the untreated (29.6% ± 7.5%) and treated (81.7% ± 6.4%) groups (p = 0.004). There was no statistically significant difference in the percentage of PDX1 + /NKX6.1 + / INS À cells (likely pancreatic progenitors) between treated and untreated groups. This indicates that these progenitors may already express insulin mRNA at a level high enough to elicit Cre-mediated excision of NTR. In contrast, there was a highly significant (p = 0.008) decrease in the percentage of PDX1 À /NKX6.1 À cells upon treatment. As for the parental line, there were no statistically significant differences between treated and untreated groups in any of the populations examined ( Figure 2D , left panel). Despite the increase in their relative percentage, addition of the pro-drugs resulted in a net decrease in b cell number ( Figure 2E , right panel), probably due to bystander (''kiss of death'') effect (Andrade-Rozental et al., 2000) . To discard the possibility that the pro-drugs may negatively affect the phenotype of the selected b-like cells, we conducted qRT-PCR of key pancreatic endocrine genes for (D) Fluorescence-activated cell sorting (FACS) analysis (percentage of live cells) for PDX1, NKX6.1, and INS in lH1-and H1 cell-derived stage 6 cells after treatment (+) with the pro-drugs GCV (100 mM) and CB1954 (10 mM). Untreated controls (0.043% DMSO) (À) are also shown for comparison. (E) FACS analysis (total cell count) for PDX1, NKX6.1, and INS, in lH1-and H1-hESC-derived stage 6 cells after treatment (+) or untreated (À) control. Error bars: standard error. ***p < 0.001, **p < 0.01, *p < 0.05. n = 6 independent experiments. Images were acquired with an inverted fluorescence microscope. both treated and untreated lH1 and H1 cells ( Figure 3A) . As expected, neither the parental line nor untreated lH1 showed significant differences. In contrast, the expression of several genes involved in insulin secretion was significantly upregulated in the lH1 cells that received both pro-drugs versus the untreated ones. This suggests that, far from exerting a deleterious effect on the function of b cells, selection and enrichment by the pro-drugs may in fact improve it. Perifused non-treated, differentiated lH1 cells exhibited a glucose-responsive insulin secretion pattern similar to that of differentiated H1 ( Figure 3B , left panel). In contrast, lH1 cells selected with GCV and CB1954 exhibit a stronger (normalized by DNA content) response than the parental line ( Figure 3B, right panel) , in all likelihood reflecting the corresponding enrichment in b cells. The perifusion response of four human islet preparations is shown for comparison in Figure S6 . Additional measurements of C-peptide at low and high glucose (Figure 3C ) and total insulin/C-peptide ( Figure 3D ), further confirm enhanced responses in the treated versus untreated lH1 groups.
Also, as predicted, lH1 cells (clone A) had nearly undetectable expression of both transgenes at the b cell stage ( Figure 3E ). For HSV-TK, this is due to lack of expression of hTERT in b cells, but not to loss of the transgene (Figure S5C ). For NTR, in contrast, lack of expression is due to loss of the transgene following Cre-mediated recombination ( Figure S5C ).
Treatment with Either GCV or CB1954 Prevents the Formation of and Eliminates Fully Formed Teratomas in Immunodeficient Mice Xenotransplanted with lH1 Cells
To test whether our strategy worked as intended in vivo, 5 3 10 6 undifferentiated lH1 cells were transplanted subcutaneously into 5-6-week-old immunodeficient NOD-SCID (non-obese diabetic-severe combined immunodeficiency) mice. Groups were assigned as follows: control (vehicle treatment, n = 3; Figure 4A ); peri-transplantation treatment with GCV (40 mg/kg; 5 days, starting the seventh day after transplantation, n = 4; Figure 4B ); and peri-transplantation treatment with CB1954 (20 mg/kg; 5 days, starting the seventh day after transplantation, n = 4; Figure 4C ). Tumors could be palpated and measured using calipers in the control group starting at week 6-7 ( Figure 4A ). At week 10, one of the mice was euthanized for histopathological characterization of the teratoma, which expectedly showed derivatives of the three germ layers ( Figure 4A ). Starting on week 11, we treated the remaining two mice with GCV and CB1954 to test whether pro-drug administration would eliminate already formed tumors. Indeed, tumor volume receded to undetectable levels within 3 weeks ( Figure 4A ).
No tumors could be detected in the GCV-pretreated group up to week 10, 4 weeks after tumors were first detected in the control group. Two mice were euthanized at this point, showing no tumors (data not shown). However, examination of the remaining two animals suggested the presence of small teratomas, so we observed them for an additional week. During this period, the tumors grew significantly. This could be due to either the carry-over of residual hESC escapees that survived the initial GCV regimen, or to the development of GCV-resistant mutations in HSV-TK, as described previously (Kotini et al., 2016) . To test these two hypotheses, we retreated these animals with GCV in a 5-day drug/2-day rest regimen for the following 3 weeks. The complete disappearance of both tumors ( Figure 4B ), as determined both by manual palpation and necropsy after euthanasia, confirmed the former hypothesis. Finally, none of the animals in the third group (treated in the peritransplantation period with CB1954) developed tumors ( Figure 4C ).
To determine whether pro-drug treatment affected functionality in vivo, we transplanted an additional 12 NOD-SCID mice with fully differentiated cells. Four mice were transplanted with 1 3 10 6 differentiated H1 cells (control group) and 8 with the same number of lH1 cells ( Figure 5A ). Out of these, four received GCV + CB1954 pre-selected lH1 cells. The remaining four were transplanted with nonselected lH1 cells and treated with the two pro-drugs 3 weeks after transplantation (dosage/regimen as above) (see Figure 5B for research scheme). Basal circulating human C-peptide was determined just prior to transplantation and at weeks 2, 4, 6, and 8 for each group. Figure 5C shows that the secretion of human C-peptide, as previously reported, follows a similar uptrend with time for all groups as they further mature in vivo (Rezania et al., 2014) . Functionality was affected neither by the genetic modification nor by the subsequent selection with the pro-drugs in vivo, as demonstrated by glucose-stimulated C-peptide release assays at weeks 6 and 8 ( Figure 5D ). At the last time point examined prior to euthanasia (week 8), there were no statistically significant differences between the three groups in human C-peptide secretion or glucose-stimulated C-peptide release. Analysis of the grafts after euthanasia revealed abundant teratoma-like lesions and OCT4 signal in the subcapsular space of mice transplanted with H1 cells (Figure 5E , top and inset). However, none of the animals transplanted with lH1 cells (whether selected in vitro or in vivo) exhibited such tumorigenic features (H&E staining of grafts following in vitro selection shown as an example, Figure 5E , bottom). Insulin-and PDX1-positive clusters were comparable in all groups, although they were more dispersed and represented a smaller proportion of the overall graft in the H1 group. Glucagon IF signal was low in the H1 group, but almost non-detectable in the others ( Figure 5F ). We conducted quantification of insulin and glucagon signal in multiple grafts within each group. As shown in Figure 5G , the number of b-cells/field was higher in lH1 cell grafts than in those of H1 cells (p < 0.005 between in vitro-treated lH1 and H1; p < 0.01 between in vivo-treated lH1 and H1). In contrast, and as expected, the number of glucagon-positive cells was significantly higher in H1 than either in vitro or in vivo-treated lH1 grafts ( Figure  5H ). Notably, $85% of the few surviving a-cells in the lH1 grafts were found to also co-express insulin ( Figure  5H , pie charts), which may explain their selective survival. Polyhormonal cells, albeit rare in current endocrine differentiation protocols, are still routinely detected (Russ et al., . Neuroectoderm (GFAP + region) was also readily detected. Scale bars, 100 mm for main panels and 50 mm for insets. Two mice exhibiting external signs of tumor growth were allowed to progress for another week and then treated at week 11 post-transplantation with GCV and CB1954. Five-day treatments are represented as shaded green colored blocks (spaces represent a 2-day rest between treatments). The tumors disappeared completely by week 14, as judged by external measurements and upon histological analysis after euthanasia. Shown in the picture is the same mouse at week 12 (exhibiting a large subcutaneous growth) and week 14, without any signs of teratoma. (B) Progression of teratoma volume in a group of mice treated with GCV for 5 days, 1-week post transplantation. Two mice euthanized at week 11 (*) did not have any tumors, as confirmed by histological analysis upon euthanasia. However, two mice developed ''escape'' tumors, probably due to insufficient GCV-induced killing of undifferentiated cells. However, further GCV treatment (3 weeks, 5-day treatment + 2-day rest, represented by blue shaded blocks) resulted in the total ablation of the tumors. 2015). Only 6% of the glucagon-expressing cells in the H1 grafts co-expressed insulin ( Figure 5H , pie chart).
DISCUSSION
The risk of iatrogenic tumorigenesis has been recognized from very early on in the context of hESC transplantation. While tumors can be treated by standard cytotoxic treatments such as radiotherapy (Marcu et al., 2018) or, more recently, oncolytic viruses (Andtbacka et al., 2015) , it stands to reason that regulatory agencies will demand the means to prevent, rather than ablate, hESC-derived teratomas (Fox, 2008) .
It has been argued that, if the number of undifferentiated cells/batch is below the threshold known to produce teratomas in immunodeficient mice, these preparations should be safe (Vogel, 2005) . However, this does not consider the risk of de-differentiation after transplantation (Fujikawa et al., 2005) . hESC-based therapies are predicted to reach millions. It would take only one clinical incidence of tumorigenesis to bring the entire field to a screeching halt, perhaps for years. It is for this reason that others have proposed the use of suicide genes under constitutive promoters (Schuldiner et al., 2003) . However, in such a setting, the pro-drug would kill the whole graft, including the cells for which there was a need in the first place. The use of the hTERT promoter driving HSV-TK has been recently described to address this problem (Tian et al., 2013 ), but such approach by itself does not offer differentiation selectivity. Our method is innovative because it allows for the selective preservation and enrichment of the desired cells while destroying those with tumorigenic potential. The provision of a double fail-safe mechanism is another feature of our system, as tumorigenic escapees would be sensitive to not one but two pro-drugs. This is of special importance following the report of GCV resistance mutations in HSV-TK (Kotini et al., 2016) , as any such mutation would compromise the entire approach. To our knowledge, no similar tactic has been described thus far. If successful, our strategy has far-reaching applications beyond diabetes. Selectivity could be adjusted for other settings by simply replacing the insulin promoter by regulatory sequences specific to the cell of interest. Our research is particularly timely in the context of hESC-derived b-like cell transplantation for the treatment of type 1 diabetes, which is now at the clinical trial stage. Owing to shortcomings of the Encaptra immunoisolation device used in their first wave of trials (Henry et al., 2018) , Viacyte has recently initiated the transplantation of non-immunoisolated hESC derivatives into immunosuppressed patients (clinicaltrials.gov identifier: The number of glucagon-positive cells was significantly higher in H1 than either in vitro or in vivo-treated lH1 grafts. The majority of the few surviving a-cells in the lH1 grafts were found to also co-express insulin (84.4% and 83.3% for in vitro and in vivo treated, respectively), which may explain their selective survival. In contrast, >93% of the glucagon + cells in the H1 grafts were mono-hormonal. NCT03163511). Therefore, the two safeguards previously featured by the approach (i.e., a physical barrier that prevented cell escape and a fully competent immune system of the host) are now gone.
Here we present evidence that the insertion of a double suicide gene cassette imparts differentiation selectivity and protection against potential tumorigenesis in hESCs. Genetically modified cells can be selected in vitro or in vivo for the enrichment of insulin-producing cells. This selection has no impact in the overall functionality of the cells, as demonstrated by a battery of tests both in vitro and after transplantation. In fact, following selection, modified hESC preparations generally exhibit stronger functional responses than their unmodified and modified/unselected counterparts, probably owing to b-like cell enrichment on a per cell basis.
It is worth mentioning that selection results in some loss of b-like cells, as expected of the bystander or kiss of death effect. In short, toxic metabolites are transmitted from pro-drug-sensitive cells to adjacent prodrug-resistant cells (Andrade-Rozental et al., 2000) . However, considering the high percentage of b-like cells in our protocol (which may have led to a high local concentration of CB1954 toxic by-products), the effect was not as marked as potentially expected. When mice were treated in vivo with both pro-drugs 3 weeks after transplantation, at the 4-week time point the overall secretion of human C-peptide was only slightly lower than that measured for parental or lH1 cells pre-selected prior to transplantation. Despite this temporary stalling, likely reflective of bystander b cell death at that point, the maturation trend remained intact (i.e., human C-peptide secretion kept increasing with time), and at the 8-week time point there were no statistically significant differences in human C-peptide secretion or glucose stimulation index between any of the three groups. Absolute C-peptide values are generally aligned, on a per cell basis, with those described in Rezania et al. (2014) , a widely considered standard in hESC-to-b cell differentiation methods.
Our study indicates that teratomas can be largely prevented by treating the recipient of the cells with the prodrugs in the peri-transplantation period. More importantly, even if some cells were to escape and eventually give rise to full-fledged teratomas, they can be safely ablated by re-administration of the two drugs. In vivo treatment still largely preserves b cell mass and function. It has been reported that constitutive Cre expression may be harmful to the cell (Janbandhu et al., 2014) , albeit only at high transgene dosages. Prolonged, low levels of Cre activity permit recombination without concomitant toxicity (Loonstra et al., 2001) . Our observation that b-like cells differentiated from lH1 cells show no functional impairment compared with their parental-derived counterparts would suggest that, in our setting, there is no meaningful Cre-associated toxicity, at least throughout the 8-week time frame on which we report. Longer-term follow-up studies would be necessary to fully ascertain any potential damage.
Although other suicide gene-based strategies to avoid tumorigenesis have been described in the literature (Hara et al., 2008; Kojima et al., 2018; Tsujimura et al., 2018) , none thus far has also provided the means to selectively preserve the cells of interest. The present study is proposed as proof-of-principle for the subsequent generation of clinical-grade hESCs in which the integration of these constructs is targeted to safe genomic harbors, minimizing the risk of insertional mutagenesis (Baum et al., 2006) and ensuring the selection of single-copy integrations. hESC lines modified in this fashion would be considered safe for transplantation.
EXPERIMENTAL PROCEDURES
Cell Culture and MTT Growth Assay hESCs (H1 clone, p. 75) were cultured as described (Schuldiner et al., 2000) using mTeSR (cat. no. 05,850, STEMCELL Technologies, Vancouver, Canada; https://www.stemcell.com/). Additional methods for plasmid generation, hESC transfection, differentiation and fluorescence-activated cell sorting/immunofluorescence analysis of differentiation outcomes are described in Supplemental Experimental Procedures.
Teratoma Assays
All animal experiments were conducted under the supervision of the University of Miami Institutional Animal Care and Use Committee. NOD-SCID mice (5-6 weeks old; Jackson Laboratory, Bar Harbor, ME, USA, https://www.jax.org) were housed in specific pathogen-free conditions at the Division of Veterinary Resources. Transplantation methods are detailed in Supplemental Experimental Procedures.
Statistics
GraphPad Prism v.5 was used for statistical analysis. Following the Shapiro-Wilk normality test, statistical differences between groups were calculated by two-tailed paired t test or Wilcoxon signed rank test with 95% confidence intervals (*p < 0.05, **p < 0.01, ***p < 0.001). Results are expressed as means ± SD. 
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